drugset / Trial / NCT00379080
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This phase I/II trial is studying the side effects and best dose of tandutinib and to see how well it works in treating patients with recurrent or progressive glioblastoma.Tandutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Timeline
- Start
- 2007-01
- Primary completion
- 2012-09
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tandutinib | Small molecule | 500 mg | Oral |
| Subject | Tandutinib | Small molecule | 600 mg | Oral |